Inventiva S.A. (IVEVF)
| Previous close | 3.6700 |
| Open | 3.6400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.6400 - 3.6400 |
| 52-week range | 3.6400 - 5.1300 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 203.146M |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.6400 |
| Earnings date | 21 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.10 |
GlobeNewswireInventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel the histological response to lanifibranor therapy in patients with MASH/NASH, in the NATIVE Phase IIb clinical trial.The second abstract brings additional evidence supporting the role of intrahepatic vascular alterations in the development of MASLD-related portal hypertension and the progression to MASH and highlights the potential of lanifibranor in a
- GlobeNewswire
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9 million, €0.01 million and €9.0 million as of December 31, 2023, respectively.The fourth scheduled DMC meeting recommended to continue the NATiV3 Phase III clinical trial without modification of the current protocol, based on the pre-planned review of interim safety data of more than 900 patients randomized in the main and exploratory co
- GlobeNewswire
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test re
